[ORGANIZATION]
daraxonrasib
Featured in 1 tracked story · first seen
Situations
Daraxonrasib trial shows doubled survival, EMA review ongo‑g
30 clusters · 135 sources · last updated
Latest: Pancreatic Cancer Advances: Vaccine Shows Safety and Drug Doubles Survival
The rolling EMA review of the oral KRAS‑targeting inhibitor daraxonrasib, launched on 7 July 2026, continues as new clinical data emerge. A multinational phase‑III trial reported on 25 July that daraxonrasib doubled medi